Area of research
Oncology · Hepatology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, and Colorectal Cancer Treatments and Studies.
A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).
LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
A phase II study of Chinese patients (pts) treated with <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC).